Adelaide de Mauleon, MD, Gérontopôle de Toulouse, Department of Geriatric Medicine, Toulouse University Hospital, 224, avenue de Casselardit, 31059 TOULOUSE Cedex 9, France; Phone: 33.5.61.77.64.26, Fax: 33.5.61.77.64.78; E-mail:
J Prev Alzheimers Dis. 2017;4(3):183-193. doi: 10.14283/jpad.2017.8.
The aims of the Research Of biomarkers in Alzheimer's diseaSe (ROSAS) study were to determine the biofluid and imaging biomarkers permitting an early diagnosis of Alzheimer's disease and better characterisation of cognitive and behavioural course of the pathology. This paper outlines the overall strategy, methodology of the study, baseline characteristics of the population and first longitudinal results from the ROSAS cohort.
Longitudinal prospective monocentric observational study performed at the Alzheimer's disease Research centre in Toulouse. A total of 387 patients were studied and analyzed in 3 groups: 184 patients with dementia of Alzheimer's type, 96 patients with memory disorders without dementia (Mild Cognitive Impairment) and 107 patients without abnormal memory tests (control group), and were followed up during 4 years. Patient's sociodemographic characteristics, risk factors, medical conditions, previous and current medications, neuropsychological assessment and overall cognitive status were recorded. Blood and urine samples were collected at every year, Magnetic Resonance Imaging were performed at inclusion, after one year of follow-up and at the end of the study.
At baseline, three different groups of the cohort differed interestingly in age, level of education, and in percentage of ApoEε4 carriers whereas the history of cardiovascular and endocrine pathologies were similar among the groups. During the follow-up period (3-4 years) 42 mild cognitive impairment patients (43.8%) progressed to dementia, 7 controls progressed into mild cognitive impairment and 1 patient in the control group converted from mild cognitive impairment group to dementia of Alzheimer's type group. During the first year of follow up, the incidence of progression from mild cognitive impairment to dementia of Alzheimer's type was 12.7 per 100, during the second year 33.9 per 100 and 46.7 per 100 for the third year.
This paper presents the baseline characteristics of the unique French prospective monocenter study in which the natural course of dementia of Alzheimer's type was evaluated. Future analysis of blood and urine samples collection from the ROSAS study will permit to identify possible biofluid biomarkers predicting the early stages of the dementia of Alzheimer's type and risk of progression from Mild Cognitive Impairment to Alzheimer's disease.
阿尔茨海默病生物标志物研究（ROSAS）的目的是确定允许早期诊断阿尔茨海默病的生物体液和成像生物标志物，并更好地描述病理学的认知和行为过程。本文概述了该研究的总体策略、研究方法、人群的基线特征以及 ROSAS 队列的首次纵向结果。
在图卢兹阿尔茨海默病研究中心进行的纵向前瞻性单中心观察性研究。共研究和分析了 387 名患者，分为 3 组：184 名阿尔茨海默病痴呆患者、96 名无痴呆记忆障碍患者（轻度认知障碍）和 107 名无异常记忆测试患者（对照组），并在 4 年内进行随访。记录患者的社会人口统计学特征、危险因素、医疗状况、既往和当前用药、神经心理学评估和整体认知状态。每年采集血液和尿液样本，在纳入时、随访 1 年后和研究结束时进行磁共振成像。
在基线时，队列的三个不同组在年龄、教育水平和载脂蛋白 Eε4 携带者的百分比方面差异显著，而心血管和内分泌病史在组间相似。在随访期间（3-4 年），42 名轻度认知障碍患者（43.8%）进展为痴呆，7 名对照者进展为轻度认知障碍，1 名对照者从轻度认知障碍组转变为阿尔茨海默病型痴呆组。在随访的第一年，从轻度认知障碍进展为阿尔茨海默病型痴呆的发病率为每 100 人 12.7 例，第二年为每 100 人 33.9 例，第三年为每 100 人 46.7 例。
本文介绍了法国独特的前瞻性单中心研究的基线特征，该研究评估了阿尔茨海默病型痴呆的自然病程。对 ROSAS 研究中血液和尿液样本采集的进一步分析将能够确定可能的生物体液生物标志物，这些标志物可预测阿尔茨海默病型痴呆的早期阶段以及从轻度认知障碍向阿尔茨海默病进展的风险。
